Accordingly, IL-15 signaling has been implicated in CD8+ TRM cell-mediated pathology in several autoimmune skin diseases [85], and blockade of the IL-15 receptor has been proposed for treatment of vitiligo [86] and alopecia areata [87], two skin conditions that are driven by pathologic CD8+ TRM cells. This evidence concerns the gene CD8A and alopecia areata.